These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20542963)

  • 1. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Ann Rheum Dis; 2010 Jul; 69(7):1275-80. PubMed ID: 20542963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.
    Buttgereit F; Kent JD; Holt RJ; Grahn AY; Rice P; Alten R; Yazici Y
    Bull Hosp Jt Dis (2013); 2015 Jul; 73(3):168-77. PubMed ID: 26535595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Lancet; 2008 Jan; 371(9608):205-14. PubMed ID: 18207016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).
    Buttgereit F; Mehta D; Kirwan J; Szechinski J; Boers M; Alten RE; Supronik J; Szombati I; Romer U; Witte S; Saag KG
    Ann Rheum Dis; 2013 Feb; 72(2):204-10. PubMed ID: 22562974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids.
    Cutolo M; Iaccarino L; Doria A; Govoni M; Sulli A; Marcassa C
    Clin Exp Rheumatol; 2013; 31(4):498-505. PubMed ID: 23415134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis.
    Ursini F; Naty S; Bruno C; Grembiale RD
    Rev Recent Clin Trials; 2017; 12(2):124-128. PubMed ID: 28356031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone.
    Alten R; Döring G; Cutolo M; Gromnica-Ihle E; Witte S; Straub R; Buttgereit F
    J Rheumatol; 2010 Oct; 37(10):2025-31. PubMed ID: 20682671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.
    Alten R; Holt R; Grahn A; Rice P; Kent J; Buttgereit F; Gibofsky A
    Scand J Rheumatol; 2015; 44(5):354-8. PubMed ID: 26114379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
    Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
    Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone chronotherapy.
    Spies CM; Cutolo M; Straub RH; Burmester GR; Buttgereit F
    Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S42-5. PubMed ID: 22018182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
    Stock T; Fleishaker D; Wang X; Mukherjee A; Mebus C
    Int J Rheum Dis; 2017 Aug; 20(8):960-970. PubMed ID: 28328159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.
    Buttgereit F; Strand V; Lee EB; Simon-Campos A; McCabe D; Genet A; Tammara B; Rojo R; Hey-Hadavi J
    RMD Open; 2019; 5(1):e000889. PubMed ID: 31168411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified-release prednisone: in patients with rheumatoid arthritis.
    Henness S; Yang LP
    Drugs; 2013 Dec; 73(18):2067-76. PubMed ID: 24249648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of glucocorticoids in rheumatoid arthritis.
    Spies CM; Bijlsma JW; Burmester GR; Buttgereit F
    Curr Opin Pharmacol; 2010 Jun; 10(3):302-7. PubMed ID: 20202903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
    Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity?
    Jurgens MS; Jacobs JW; Geenen R; Bossema ER; Bakker MF; Bijlsma JW; van Albada-Kuipers IA; Ehrlich JC; Lafeber FP; Welsing PM;
    Arthritis Care Res (Hoboken); 2013 Jan; 65(1):88-93. PubMed ID: 22807253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.
    van Everdingen AA; Jacobs JW; Siewertsz Van Reesema DR; Bijlsma JW
    Ann Intern Med; 2002 Jan; 136(1):1-12. PubMed ID: 11777359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fresh look at glucocorticoids how to use an old ally more effectively.
    Buttgereit F
    Bull NYU Hosp Jt Dis; 2012; 70 Suppl 1():26-9. PubMed ID: 23259655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis.
    Krasselt M; Baerwald C
    Drug Des Devel Ther; 2016; 10():1047-58. PubMed ID: 27022244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.